EFS
ALXN

Essex Financial Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Essex Financial Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,872
Closed -$260K – 303
2018
Q3 		$260K Hold
1,872
– – 0.06% 235
2018
Q2 		$232K Buy
+1,872
New +$219K 0.06% 240

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Essex Financial Services's ALXN Position: Q4 2018 in Review

Essex Financial Services sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 1,872 shares — an estimated $260K sold.

Essex Financial Services first reported a position in ALXN in Q2 2018 and held it in 2 quarters. The position peaked at $260K in Q3 2018. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Essex Financial Services reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Essex Financial Services sold 1,872 Alexion Pharmaceuticals shares in Q4 2018, an estimated $260K.
  • Essex Financial Services first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Essex Financial Services's Alexion Pharmaceuticals position peaked at $260K in Q3 2018.
  • 609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Essex Financial Services's 13F filing for Q4 2018, filed 7 Feb 2019.